更新了 MVEC 免疫参考页面：儿童和青少年的 COVID-19 疫苗接种页面
MVEC’s COVID-19 vaccination in children and the adolescent reference page has been updated to include the current recommendations for children under 5 years of age. This resource details:
- Recommended COVID-19 vaccine schedule information for children and adolescents aged ≥ 6 months
- Information on the efficacy and side effects of COVID-19 vaccination in the paediatric population
- Links to current ATAGI COVID-19 vaccine recommendations in the various paediatric and adolescent age groups
要查看完整页面，请点击以下链接：
新的免疫参考页面 – 猴痘
猴痘是一种病毒性人畜共患病（一种从动物传播给人类的感染）。它是由属于 正痘病毒 genus (which also causes the variola virus responsible for smallpox disease and the vaccinia virus, which is used in smallpox vaccines). Since the eradication of smallpox in 1980, monkeypox has become the most important orthopoxvirus affecting humans, however, causes less severe disease than smallpox.
The incubation period of monkeypox is usually 7-14 days, with initial symptoms of monkeypox including fever, headache, backache and muscle aches, fatigue and lymphadenopathy. Historically, smallpox vaccines have been used in the prevention of smallpox infection, however, they are also likely to be effective against monkeypox.
There are two types of smallpox vaccines registered for use in Australia for the prevention of monkeypox, ACAM2000™ and JYNNEOS®.
Our new reference page outlines symptoms, transmission routes, epidemiology, current vaccine recommendations and links to the latest resources.
For further information, click on the link below:
MVEC：猴痘
ATAGI 关于 5 岁以下儿童使用 COVID-19 疫苗的建议
ATAGI have now recommended COVID-19 vaccination for some children aged 6 months – 5 years. Eligible groups include those with severe immunocompromise, a disability with severe or complex health needs, or those with multiple/complex health conditions that increase the risk of severe COVID-19 disease.
A paediatric formula of the Moderna COVID-19 vaccine has been approved by the TGA in this age group for children in the groups mentioned above. A primary two-dose schedule, 8 weeks apart is recommended, with the dose being 25mcg. Children in this age group with severe immunocompromise are recommended to complete a 3-dose primary schedule.
基于一系列因素，ATAGI 目前不建议不属于上述类别的 6 个月至 5 岁儿童接种 COVID 疫苗。
随着替代品牌或变体 COVID-19 疫苗在这个年龄段可用，或者如果出现流行病学变化（例如出现新的令人担忧的变体），建议可能会发生变化。
To read the recommendations in full please follow the link below.
ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years
COVID-19 疫苗对超过 200,000 名澳大利亚儿童的安全性：来自 AusVaxSafety 的令人放心的数据
New AusVaxSafety research which analysed 392,268 survey responses via AusVaxSafety’s national active safety surveillance system between July 2021 and May 2022, has found that Australian children aged 5-15 years report fewer side effects in the days following mRNA COVID-19 vaccination than those reported in clinical trials and published safety data.
Importantly, fever was reported low in the youngest age group, comparable to that seen following annual influenza vaccination. Additionally, there were also no self-reported cases of myocarditis and pericarditis identified in the study.
AusVaxSafety will commence surveillance in children aged 6 months to 5 years once COVID-19 vaccines become available in this age group.
To access the research in full, click on the link below.
Safety of COVID-19 vaccines in >200,000 Aussie kids: reassuring data from AusVax安全
Flinders University Alumni publication featuring A/Prof Nigel Crawford: Providing the vital boost for us to fight COVID-19
MVEC’s Associate Professor Nigel Crawford was featured in the Flinders University College of Medicine and Public Health Alumni magazine regarding his significant contribution to Australia’s COVID-19 vaccine rollout. As the current chair of the Australian Technical Advisory Group for Immunisation (ATAGI), Nigel discusses his role in steering Australia’s uptake of COVID-19 vaccines, including effective communication and the ability to remain flexible when responding to and adapting vaccine advice for the general public.
To read the full article, follow the link below.
Registrations opening soon for our next CVU mini August event
MVEC’s next Clinical Vaccinology Update (CVU) mini event on COVID-19: infection and vaccines in children aged 6 months and over will take place virtually in August, with the date to be announced shortly. This CVU mini will provide an update on:
- 针对 6 个月以上澳大利亚儿童的 COVID-19 疫苗建议
- 儿童 COVID-19 疫苗的安全性
The event program and link to register will be available shortly via our Events page or via the link below.
New resource for adults added to the MVEC immunisation information hub for the general public
Immunisation throughout life is an important way to remain protected against vaccine preventable diseases, and not only protects the individual, but more vulnerable members of society.
Our dedicated immunisation resource for the general public includes information on the HALO principle when considering immunisation for adults, Health, Age, Lifestyle and Occupation, as well as vaccine recommendations, answers to frequently asked questions and links to further resources.
MVEC’s hub of up-to-date and reliable information aims to increase the public’s awareness and understanding of vaccine preventable diseases and promote the benefits of immunisation for people of all ages.
If you are interested in collaborating with MVEC to develop immunisation resources, we’d love to hear from you!
To access this new resource for seniors, please click on the link below.
MVEC’s Immunisation hub for the general public
Save the date for our 2022 Clinical Vaccinology Update!
MVEC are pleased to announce that our next Clinical Vaccinology Update (CVU) will take place on Friday 28 October. The event will be held in-person at the University of Melbourne.
The CVU will provide an opportunity for immunisation providers, industry partners and vaccine experts to come together for interactive professional development and networking.
Program details and ticketing information will be announced shortly via our MVEC Events Page
对话：针对 5 岁以下儿童的 COVID 疫苗即将问世。这是父母需要知道的
治疗用品管理局 (TGA) 已临时批准了适用于 6 个月以上儿童的 Moderna COVID-19 疫苗儿科剂量。
MVEC 的 Daryl Cheng 博士和 Margie Danchin 副教授探讨了在澳大利亚向该人群推出 Moderna 疫苗之前父母需要了解的内容，包括疫苗的安全性和有效性以及在该年龄段接种疫苗的好处和影响本文。
要阅读全文，请点击以下链接：
对话：针对 5 岁以下儿童的 COVID 疫苗即将问世。这是父母需要知道的
Updated MVEC immunisation reference page: Travel medicine
Travel medicine focuses on disease prevention and injury risk minimisation for anyone travelling internationally. Recommendations can be based upon the travelling person’s individual circumstances such as the location and purpose of travel, duration and time of year of travel, as well as any underlying medical conditions or other risk factors.
MVEC’s reference page on 旅行药 has recently been updated. This resource outlines:
- where to get travel advice and when to seek advice
- vaccines for travellers
- immunocompromised and pregnant travellers
- advice for visiting friends and relatives (VFR).
要查看完整页面，请点击以下链接：
MVEC: Travel medicine